Effect of rhPTH(1-34) and alendronate on the treatment of type 2 diabetic bone disease.
Saved in:
| Title: | Effect of rhPTH(1-34) and alendronate on the treatment of type 2 diabetic bone disease. |
|---|---|
| Authors: | Li H; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.; Institute of Osteoporosis and Metabolic Bone Diseases, School of Medicine, Tongji University, Shanghai, China., Yuan L; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.; Institute of Osteoporosis and Metabolic Bone Diseases, School of Medicine, Tongji University, Shanghai, China., Liu P; Yichuan Community Health Service Center of Putuo District, Shanghai, China., Liu Y; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China., Huang D; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China., Ding H; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China., Jin W; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.; Institute of Osteoporosis and Metabolic Bone Diseases, School of Medicine, Tongji University, Shanghai, China., Liu J; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.; Institute of Osteoporosis and Metabolic Bone Diseases, School of Medicine, Tongji University, Shanghai, China., Wang H; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.; Institute of Osteoporosis and Metabolic Bone Diseases, School of Medicine, Tongji University, Shanghai, China., Song L; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.; Institute of Osteoporosis and Metabolic Bone Diseases, School of Medicine, Tongji University, Shanghai, China. |
| Source: | Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2025 Sep 15; Vol. 16, pp. 1657481. Date of Electronic Publication: 2025 Sep 15 (Print Publication: 2025). |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-2392 |
|---|---|
| DOI: | 10.3389/fendo.2025.1657481 |
